Boulegeris Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boulegeris Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,175	Closed	-$542K	–	53
2015 Q4	$542K	Sell	5,175 -285	-5%	-$29.8K	0.39%	35
2015 Q3	$575K	Buy	5,460 +940	+21%	+$126K	0.44%	35
2015 Q2	$618K	Buy	4,520 +525	+13%	+$65.1K	0.44%	34
2015 Q1	$498K	Buy	3,995 +1,495	+60%	+$158K	0.37%	36
2014 Q4	$226K	Buy	+2,500	New	+$208K	0.18%	42

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boulegeris Investments's BMRN Position: Q1 2016 in Review

Boulegeris Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 5,175 shares — an estimated $542K sold.

Boulegeris Investments first reported a position in BMRN in Q4 2014 and held it in 5 quarters. The position peaked at $618K in Q2 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Boulegeris Investments reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Boulegeris Investments sold 5,175 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $542K.
Boulegeris Investments first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Boulegeris Investments's BioMarin Pharmaceuticals position peaked at $618K in Q2 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Boulegeris Investments's 13F filing for Q1 2016, filed 5 May 2016.